SynBioBeta Speaker
Ignacio Massone
Resistia
CEO & Co-founder
Ignacio brings nearly a decade of senior leadership experience from the biopharma industry, primarily at GSK. As Sr. Business Manager for Vaccines and Specialties markets, he led strategic initiatives that positively impacted the lives of thousands of patients while delivering consistent double-digit growth. His expertise lies in go-to-market execution, stakeholder alignment, and high-performance team leadership. Ignacio holds a degree in Business Management from UCA and has completed executive education at the Kellogg and ESCP Business School. He is dedicated to bridging the gap between world-class scientific research and scalable clinical solutions to address urgent global health challenges like antimicrobial resistance (AMR). He is currently the CEO and co-founder of Resistia, where they are developing a therapeutic platform based on healthy microbiota to re-empower existing antibiotics and cure biofilm-resistant infections. Resistia is currently part of the Blueprint program by The Engine (MIT) and was recently selected as a pitching finalist at the 10th AMR Conference in Basel.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Ignacio
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
